Press Releases<< Back
CHF Solutions, Inc. Begins New Educational Program, “Facing the Facts About Fluid Overload” to Demonstrate the Need for Aquadex Therapy
"Intravenous diuretics have been the standard of care for heart failure patients with fluid overload since the 1950s1,2, but data demonstrates that 68 percent of patients experience a less than optimal response, and approximately 40 percent are resistant to diuretic therapy3. Many physicians simply are not aware that the Aquadex FlexFlow System can address the unmet clinical need for these patients when diuretic resistance is encountered,” commented
This educational campaign will also raise awareness of the potential economic impact that fluid overloaded patients may have on hospitals and the healthcare system. It has been shown in clinical trials that 24 percent of heart failure patients that are discharged from the hospital are readmitted within 30 days, and 50 percent within 6 months4,5. Conversely, ultrafiltration therapy with the Aquadex FlexFlow system has demonstrated a 53 percent reduction in the risk of re-hospitalization of heart failure patients6. Further, data demonstrates that nearly half of all patients discharged from the hospital with heart failure are still fluid overloaded at time of discharge7. The Aquadex FlowFlow System provides a solution for safe and precise fluid removal for patients with volume overload who have failed diuretic therapy.
About CHF Solutions
Chief Financial Officer
Sources: 1. Freis ED, Wanko A, Wilson IM, et al. JAMA 1958;166 (2) 137- 140. 2. Moser M, Macauley AI, Am J Cardiol 1959;3 (2) 214- 219. 3. Testani JM, Hanberg JS, Cheng S, et al. Circ Heart Failure. 2016;9(1). 4. Ambrosy, Fonarow GC, Butler J, et al. J Am Coll Cardiol. 2014;63:1123-33. 5. Crespo-Leiro MG, Anker SD, Maggioni AP et al. Eur J Heart Fail 2016;18: 613-25. 6. Costanzo MR, Guglin ME, Saltzberg MT, et al. J Am Coll Cardiol. 2007;49(6):675-683. 7. Gheorghiade M and Flippatos G. Eur Heart J Suppl 2005;7: B13-19.
Source: CHF Solutions, Inc.